The encouraging findings are mostly from laboratory and follicle-culture studies, and the closest human study tested copper peptides in combination with another agent, not on their own
10.2174/156802611797183230 Curr
21, 22 However, the current debate on the validity of the postmenopausal data and the lack of CYP2D6 association with clinical outcome in some of these studies 21, 22, 23, 24, 25, 26, 27, 28 point to the need of combined pharmacokinetic and pharmacogenetic analyses particularly in the case of testing the hypothesis in another patient group, i.e
The genetic test reveals predispositions in peptide pathway signaling that may correlate with responder phenotypes described in clinical literature
Improves Overall wellbeing
Volkow y sus colegas publicaron un estudio en 2024 que sugera que los GLP-1 tambin podran reducir el deseo de consumir cannabis